Moderna stock rises 3.4% due to increasing flu cases, along with other vaccine companies.

From Investing.com: 2025-01-07 07:54:59

Shares of Moderna and CureVac are on the rise in premarket trading as flu cases surge in the US. Moderna’s stock climbed 3.4% while CureVac soared 5%, following broader gains in the vaccine sector. Novavax and BioNTech also saw increases, with the CDC reporting a spike in flu activity and positive lab tests.

The CDC’s latest data shows a concerning trend with 18.7% of clinical lab tests positive for influenza. Outpatient visits for respiratory illness have risen to 6.8%, remaining above the national baseline for the fifth consecutive week. The surge in flu cases has prompted renewed emphasis on annual flu vaccinations and prompt antiviral treatment.

The first reported death from bird flu in the US has been confirmed by the Louisiana Department of Health. The individual, aged over 65 with pre-existing conditions, contracted the virus through exposure to birds. With 5.3 million flu cases, 63,000 hospitalizations, and 2,700 deaths this season, the CDC is closely monitoring flu alongside COVID-19 and RSV.

Investors are reacting to increased demand for vaccines and treatments due to heightened flu activity. The market’s response underscores the essential role of vaccine developers in public health during periods of elevated disease prevalence. The focus on flu prevention and treatment is expected to remain as the season progresses, reflecting the importance of vaccination efforts.



Read more at Investing.com: Moderna stock gains on rising flu cases By Investing.com